Skip to content

Aneuploidies and Different Stimulation Protocols

Influence of Ovarian Stimulation and Embryo Aneuploidy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00802295
Enrollment
30
Registered
2008-12-04
Start date
2008-12-31
Completion date
2009-04-30
Last updated
2009-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneuploidy

Keywords

Ovarian, hyperstimulation, Embryo, Aneuploidy, Ovarian hyperstimulation and Embryo Aneuploidy Rates

Brief summary

Our working hypothesis is that patients undergoing in vitro fertilization (IVF) with higher response to ovarian stimulation protocols recover a higher number of oocytes and, this elevated response could be translated into increased incidence of chromosomally abnormal embryos. Our objective is to develop a prospective study on healthy young donors, with a previous cycle with high ovarian response (\>20 oocytes and/or E2 levels the day of the hCG injection \>3000 pg/mL), but without developing mild or severe hyperstimulation syndrome. After signing a proper written consent, these donors would agree to undergo two subsequent stimulation cycles following two different protocols. In one cycle the stimulation pattern would be similar to the previous one, with elevated response and, in another cycle the amount of gonadotropins would be cut down in order to obtain lower ovarian response. Oocytes obtained in each cycle would be donated to anonymous recipients and after fertilization, embryo quality and chromosomal status of the resulting embryos would be evaluated. Preimplantation genetic diagnosis (PGD) will be performed on day-3 embryos and chromosomes 13, 15, 16, 17, 18, 21, 22, X and Y would be analyzed by fluorescence in situ hybridization (FISH).

Interventions

Administration of standard ovarian stimulation protocol

DRUGLow dosis Gonadotrophin

Sponsors

Instituto Valenciano de Infertilidad, IVI VALENCIA
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 29 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy women between 18 - 29 * with previous cycle with standard dosis of Gonadotrophin and high response to the treatment (\> 20 oocytes) * No symptom of OHSS

Exclusion criteria

* donors with 2 previous miscarriages * PCO * Severe Male Factor

Design outcomes

Primary

MeasureTime frame
Aneuploidy rate with two different stimulation protocols.three months

Secondary

MeasureTime frame
Normal blastocyst ratethree months

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026